Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9233221 | 0.98 | FAAH (0.57) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL19031909 | 0.92 | FAAH (0.61) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL29279616 | 0.92 | FAAH (0.61) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL654707 | 0.92 | FAAH (0.61) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL7645233 | 0.92 | FAAH (0.61) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL4912158 | 0.92 | FAAH (0.50) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL19031896 | 0.92 | FAAH (0.61) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9998478 | 0.90 | FAAH (0.59) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL5873220 | 0.90 | FAAH (0.58) | FAAHCNR1CNR2ZDHHC7ALDH1A1 | |
| SCHEMBL329574 | 0.88 | FAAH (0.57) | FAAHCNR1CNR2ZDHHC7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283647-A | Prodrug modulators that integrate stress pathways | 卡里科生命科学有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230130333-A1 | METHOD FOR MANUFACTURING PHOSPHONATE ESTERS AND METHOD FOR MANUFACTURING PHOSPHATE ESTERS | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-3864003-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20080161394-A1 | Cosmetic composition comprising at least one volatile carbonic acid ester | L'OREAL S.A. (FR) | 2008-07-03 | — | — | US | disclosed |
| US-7198827-B1 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-0060904-B1 | A PROCESS FOR MAKING VICINAL EPOXIDES AND ALKYL HALIDES OR ALKYLENE DIHALIDES FROM CARBONATE ESTERS | THE DOW CHEMICAL COMPANY (US) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130333-A1 | METHOD FOR MANUFACTURING PHOSPHONATE ESTERS AND METHOD FOR MANUFACTURING PHOSPHATE ESTERS | PHOSPHO1, PHYKPL, PIK3CA | FAAH 3810/4885CNR1 4330/4885CNR2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.